Clinical Trials

Offices

For This Service

To learn more, please call our Research Department at (513) 751-2273 or email mhoelle@ohcare.com

  • Non-Small

neoadjuvant
Study number: LUN 186 SCRI
Protocol title: Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients with Select Stage IB, II, and III Non-Squamous Non-Small Cell Lung Cancer
Status Open

stage IIIB/IV, first-line
Study number:
LUN 183 SCRI
Protocol title:
A Phase II Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous K-ras Wild Type Non-Small Cell Lung Cancer
Status
Open

 
Study number:
LUN 196 SCRI
Protocol title:
TOPPS (Trial of Poor Performance Status patients): Randomized Phase II Trial of Pemetrexed vs. Pemetrexe/Bevacizumab vs. Pemetrexed/ Carboplatin/Bevacizumab in Patients with Stage III/IV Non-Small Cell Lung Cancer and ECOG Performance Status 2
Status
Open

Relapsed/refractory
Study number:
LUN 215 Infinity Pharmaceuticals IPI-504-14
Protocol title:
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer
Status
Open

Cachexia
Study number: Medpace/Cachexia Helsinn Therapeutics HT-ANAM-302
Protocol title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-C
Status Open

  • Small Cell

first line
Study number: LUN 218 Chorus I2V-MC-CXAC
Protocol title: A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide versus Carboplatin/Etoposide in Extensive-Stage Small Cell Lung Cancer
Status Open